Michael Cleary
Academic Appointments
- Professor, Pathology
- Member, Child Health Research Institute
- Member, Stanford Cancer Institute
- Professor, Pediatrics
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 723-5471
Professional Overview
Administrative Appointments
- Associate Chair for Experimental Pathology, Stanford University School of Medicine - Pathology (2004 - present)
- Director of Pediatric Cancer Biology, Stanford University School of Medicine - Pediatrics (2002 - present)
Professional Education
| B.A.: | The College of Wooster, Chemistry (1974) |
| M.S.: | The University of South Carolina, Chemistry (1976) |
| M.D.: | The University of Cincinnati, Medicine (1981) |
Graduate & Fellowship Program Affiliations
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Our research focuses on developmental pathways that regulate hematopoietic cell growth and differentiation and are disrupted in the course of neoplastic transformation, particularly in leukemias and lymphomas. We employ a variety of experimental systems for our studies ranging from molecular biology to transgenic and knockout mice. Our current interests are:
1) Characterize novel families of oncoproteins (Pbx and Meis) that dimerize with and regulate the DNA binding properties of Hox proteins. We are investigating how Pbx and Meis proteins contribute to the specificity of Hox function in development and how disruption of their activities leads to neoplasia.
2) We have discovered a group of oncoproteins that are implicated in long-term maintenance of gene expression through their effects on the state of chromatin. We are studying the role that normal chromatin structure plays in gene regulation in hematopoietic cells and how its disruption leads to altered development and cancer.
3) We are defining the properties of cancer stem cells that initiate and sustain the unique disease features of acute leukemias through the use of various adoptive animal models.
Our studies have demonstrated that several of the proteins encoded by cellular oncogenes function in fundamental aspects of gene regulation. These are frequently activated by fusion to other transcriptional proteins resulting in chimeric transcription factors. We are studying the effects and consequences of protein fusion on the transcriptional and transforming activities of these proteins using in vitro and animal models.
In addition to these basic issues concerning leukemia pathogenesis, we are devising new diagnostic procedures for detecting and monitoring leukemia patients based on molecular genetic abnormalities in the malignant cells.
Publications
- GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell. 2010; (6): 597-608
- Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009; (2): 129-40
- Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008; (7217): 1205-9
- Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008; (1): 36-46
- Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. Cell Stem Cell. 2008; (5): 484-96
- Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006; (4): 257-68
Help
Trial Administration